FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067593119> ?p ?o ?g. }

• W2067593119 abstract "Background Hypertension is a major risk factor for stroke, coronary artery disease and kidney damage in adults. There is a paucity of data on the long‐term sequelae of persistent hypertension in children, but it is known that children with hypertension have evidence of end organ damage and are at risk of hypertension into adulthood. The prevalence of hypertension in children is rising, most likely due to a concurrent rise in obesity rates. In children with hypertension, non‐pharmacological measures are often recommended as first‐line therapy, but a significant proportion of children will eventually require pharmacological treatment to reduce blood pressure, especially those with evidence of end organ damage at presentation or during follow‐up. A systematic review of the effects of antihypertensive agents in children has not previously been conducted. Objectives To determine the dose‐related effects of different classes of antihypertensive medications, as monotherapy compared to placebo; as combination therapy compared to placebo or a single medication; or in comparisons of various doses within the same class, on systolic or diastolic blood pressure (or both) in children with hypertension. Search methods We searched the Cochrane Hypertension Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 9), Ovid MEDLINE (1946 to October 2013), Ovid EMBASE (1974 to October 2013) and bibliographic citations. Selection criteria The selection criteria were deliberately broad due to there being few clinical trials in children. We included randomised controlled trials (RCTs) of at least two weeks duration comparing antihypertensive agents either as monotherapy or combination therapy with either placebo or another medication, or comparing different doses of the same medication, in children with hypertension. Hypertension was defined as an average (over a minimum of three readings) systolic or diastolic blood pressure (or both) on the 95th percentile or above for age, height and gender. Data collection and analysis Two authors independently selected relevant studies, extracted data and assessed risk of bias. We summarised data, where possible, using a random‐effects model. Formal assessment of heterogeneity was not possible because of insufficient data. Main results A total of 21 trials evaluated antihypertensive medications of various drug classes in 3454 hypertensive children with periods of follow‐up ranging from three to 24 weeks. There were five RCTs comparing an antihypertensive drug directly with placebo, 12 dose‐finding trials, two trials comparing calcium channel blockers with angiotensin receptor blockers, one trial comparing a centrally acting alpha blocker with a diuretic and one trial comparing an angiotensin‐converting enzyme inhibitor with an angiotensin receptor blocker. No randomised trial was identified that evaluated the effectiveness of antihypertensive medications on target end organ damage. The trials were of variable quality and most were funded by pharmaceutical companies. Among the angiotensin receptor blockers, candesartan (one trial, n = 240), when compared to placebo, reduced systolic blood pressure by 6.50 mmHg (95% confidence interval (CI) ‐9.44 to ‐3.56) and diastolic blood pressure by 5.50 mmHg (95% CI ‐9.62 to ‐1.38) (low‐quality evidence). High dose telmisartan (one trial, n = 76), when compared to placebo, reduced systolic blood pressure by ‐8.50 (95% CI ‐13.79 to ‐3.21) but not diastolic blood pressure (‐4.80, 95% CI ‐9.50 to 0.10) (low‐quality evidence). Beta blocker (metoprolol, one trial, n = 140), when compared with placebo , significantly reduced systolic blood pressure by 4.20 mmHg (95% CI ‐8.12 to ‐0.28) but not diastolic blood pressure (‐3.20 mmHg 95% CI ‐7.12 to 0.72) (low‐quality evidence). Beta blocker/diuretic combination (Bisoprolol/hydrochlorothiazide, one trial, n = 94)when compared with placebo , did not result in a significant reduction in systolic blood pressure (‐4.0 mmHg, 95% CI ‐8.99 to ‐0.19) but did have an effect on diastolic blood pressure (‐4.50 mmHg, 95% CI ‐8.26 to ‐0.74) (low‐quality evidence). Calcium channel blocker (extended‐release felodipine,one trial, n = 133) was not effective in reducing systolic blood pressure (‐0.62 mmHg, 95% CI ‐2.97 to 1.73) or diastolic blood pressure (‐1.86 mmHg, 95% CI ‐5.23 to 1.51) when compared with placebo. Further, there was no consistent dose response observed among any of the drug classes. The adverse events associated with the antihypertensive agents were mostly minor and included headaches, dizziness and upper respiratory infections. Authors' conclusions Overall, there are sparse data informing the use of antihypertensive agents in children, with outcomes reported limited to blood pressure and not end organ damage. The most data are available for candesartan, for which there is low‐quality evidence of a modest lowering effect on blood pressure. We did not find evidence of a consistent dose response relationship for escalating doses of angiotensin receptor blockers, calcium channel blockers or angiotensin‐converting enzyme inhibitors. All agents appear safe, at least in the short term." @default.
• W2067593119 created "2016-06-24" @default.
• W2067593119 creator A5038938109 @default.
• W2067593119 creator A5058056616 @default.
• W2067593119 creator A5059325442 @default.
• W2067593119 creator A5079598977 @default.
• W2067593119 creator A5082634620 @default.
• W2067593119 date "2014-02-01" @default.
• W2067593119 modified "2023-09-24" @default.
• W2067593119 title "Pharmacological interventions for hypertension in children" @default.
• W2067593119 cites W1493429978 @default.
• W2067593119 cites W1522833532 @default.
• W2067593119 cites W1527734194 @default.
• W2067593119 cites W1569397321 @default.
• W2067593119 cites W1970351523 @default.
• W2067593119 cites W1978204344 @default.
• W2067593119 cites W1978860275 @default.
• W2067593119 cites W1986336227 @default.
• W2067593119 cites W1993039788 @default.
• W2067593119 cites W2001173389 @default.
• W2067593119 cites W2004248853 @default.
• W2067593119 cites W2004806774 @default.
• W2067593119 cites W2005975830 @default.
• W2067593119 cites W2012516811 @default.
• W2067593119 cites W2016395844 @default.
• W2067593119 cites W2016487162 @default.
• W2067593119 cites W2018567666 @default.
• W2067593119 cites W2019150071 @default.
• W2067593119 cites W2028316404 @default.
• W2067593119 cites W2031005241 @default.
• W2067593119 cites W2032285823 @default.
• W2067593119 cites W2035446971 @default.
• W2067593119 cites W2035723635 @default.
• W2067593119 cites W2044376774 @default.
• W2067593119 cites W2044454891 @default.
• W2067593119 cites W2051167333 @default.
• W2067593119 cites W2051514221 @default.
• W2067593119 cites W2053287639 @default.
• W2067593119 cites W2069332856 @default.
• W2067593119 cites W2070908299 @default.
• W2067593119 cites W2078265054 @default.
• W2067593119 cites W2079403112 @default.
• W2067593119 cites W2092509345 @default.
• W2067593119 cites W2112999945 @default.
• W2067593119 cites W2118194784 @default.
• W2067593119 cites W2131561862 @default.
• W2067593119 cites W2131603565 @default.
• W2067593119 cites W2133533440 @default.
• W2067593119 cites W2134413555 @default.
• W2067593119 cites W2136063905 @default.
• W2067593119 cites W2139805666 @default.
• W2067593119 cites W2146285346 @default.
• W2067593119 cites W2156121263 @default.
• W2067593119 cites W2156210803 @default.
• W2067593119 cites W2162604080 @default.
• W2067593119 cites W2168160764 @default.
• W2067593119 cites W2171565306 @default.
• W2067593119 cites W2189612961 @default.
• W2067593119 cites W2288605373 @default.
• W2067593119 cites W2562329777 @default.
• W2067593119 cites W4230204649 @default.
• W2067593119 cites W4241705079 @default.
• W2067593119 doi "https://doi.org/10.1002/14651858.cd008117.pub2" @default.
• W2067593119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25236305" @default.
• W2067593119 hasPublicationYear "2014" @default.
• W2067593119 type Work @default.
• W2067593119 sameAs 2067593119 @default.
• W2067593119 citedByCount "29" @default.
• W2067593119 countsByYear W20675931192015 @default.
• W2067593119 countsByYear W20675931192016 @default.
• W2067593119 countsByYear W20675931192017 @default.
• W2067593119 countsByYear W20675931192018 @default.
• W2067593119 countsByYear W20675931192019 @default.
• W2067593119 countsByYear W20675931192021 @default.
• W2067593119 countsByYear W20675931192022 @default.
• W2067593119 countsByYear W20675931192023 @default.
• W2067593119 crossrefType "journal-article" @default.
• W2067593119 hasAuthorship W2067593119A5038938109 @default.
• W2067593119 hasAuthorship W2067593119A5058056616 @default.
• W2067593119 hasAuthorship W2067593119A5059325442 @default.
• W2067593119 hasAuthorship W2067593119A5079598977 @default.
• W2067593119 hasAuthorship W2067593119A5082634620 @default.
• W2067593119 hasBestOaLocation W20675931191 @default.
• W2067593119 hasConcept C118552586 @default.
• W2067593119 hasConcept C126322002 @default.
• W2067593119 hasConcept C127413603 @default.
• W2067593119 hasConcept C142724271 @default.
• W2067593119 hasConcept C17744445 @default.
• W2067593119 hasConcept C177713679 @default.
• W2067593119 hasConcept C187212893 @default.
• W2067593119 hasConcept C199539241 @default.
• W2067593119 hasConcept C204787440 @default.
• W2067593119 hasConcept C27081682 @default.
• W2067593119 hasConcept C27415008 @default.
• W2067593119 hasConcept C2779473830 @default.
• W2067593119 hasConcept C2780645631 @default.
• W2067593119 hasConcept C44249647 @default.
• W2067593119 hasConcept C535046627 @default.
• W2067593119 hasConcept C71924100 @default.
• W2067593119 hasConcept C78519656 @default.

• next